Nothing Special   »   [go: up one dir, main page]

BR0215148A - Composições farmacêuticas de agonista parcial 5ht4 - Google Patents

Composições farmacêuticas de agonista parcial 5ht4

Info

Publication number
BR0215148A
BR0215148A BR0215148-0A BR0215148A BR0215148A BR 0215148 A BR0215148 A BR 0215148A BR 0215148 A BR0215148 A BR 0215148A BR 0215148 A BR0215148 A BR 0215148A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
partial agonist
weight
amount
agonist pharmaceutical
Prior art date
Application number
BR0215148-0A
Other languages
English (en)
Inventor
Jerome Aubert
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0215148A publication Critical patent/BR0215148A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS DE AGONISTA PARCIAL 5HT4". A presente invenção refere-se a uma composição farmacêutica sólida para administração oral compreendendo tegaserod em forma de base ou sal em uma quantidade de até 10% em peso e um agente de massa em uma quantidade de 70 a 90% em peso, um desintegrante em uma quantidade de menos que 15% em peso, um agente de deslizamento e um lubrificante.
BR0215148-0A 2001-12-21 2002-12-20 Composições farmacêuticas de agonista parcial 5ht4 BR0215148A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR0215148A true BR0215148A (pt) 2004-10-19

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215148-0A BR0215148A (pt) 2001-12-21 2002-12-20 Composições farmacêuticas de agonista parcial 5ht4

Country Status (31)

Country Link
US (2) US20050106236A1 (pt)
EP (2) EP1321142A1 (pt)
JP (1) JP4718776B2 (pt)
KR (1) KR100980144B1 (pt)
CN (1) CN100464749C (pt)
AR (1) AR037937A1 (pt)
AT (1) ATE320807T1 (pt)
AU (1) AU2002361198B2 (pt)
BR (1) BR0215148A (pt)
CA (1) CA2470668C (pt)
CO (1) CO5640102A2 (pt)
CY (1) CY1105559T1 (pt)
DE (1) DE60210139T2 (pt)
DK (1) DK1458377T3 (pt)
EC (1) ECSP105163A (pt)
EG (1) EG24194A (pt)
ES (1) ES2258171T3 (pt)
HU (1) HU226589B1 (pt)
IL (2) IL162451A0 (pt)
MX (1) MXPA04006157A (pt)
MY (1) MY139546A (pt)
NO (1) NO20042779L (pt)
NZ (1) NZ533585A (pt)
PE (1) PE20030872A1 (pt)
PL (1) PL369509A1 (pt)
PT (1) PT1458377E (pt)
RU (1) RU2322978C2 (pt)
SI (1) SI1458377T1 (pt)
TW (1) TWI260221B (pt)
WO (1) WO2003053432A1 (pt)
ZA (1) ZA200404467B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300647B6 (cs) * 1998-08-21 2009-07-08 Novartis Ag Pevný farmaceutický prípravek pro perorální podávání obsahující tegaserod nebo jeho farmaceuticky prijatelnou sul
SI1911763T1 (sl) 2003-01-28 2010-11-30 Ironwood Pharmaceuticals Inc Sestavki za zdravljenje gastrointestinalnih motenj
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
EP1629280A2 (en) * 2003-05-21 2006-03-01 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
DK2821067T3 (en) 2003-09-12 2017-12-04 Amgen Inc Quick solution formulation of cinacalcet
US20050165085A1 (en) * 2003-12-16 2005-07-28 Marioara Mendelovici Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
BR112015003527A2 (pt) 2012-08-21 2017-07-04 Ardelyx Inc compostos e métodos para inibição de antiporte mediado por nhe no tratamento de desordens associadas à retenção de fluido ou sobrecarga de sal e desordens do trato gastrointestinal
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
HUE044550T2 (hu) 2013-04-12 2019-11-28 Ardelyx Inc NHE-3 megkötõ vegyületek és foszfát transzport gátlási módszerek
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
AU2018205400B2 (en) 2017-01-09 2022-07-14 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
CN110291082A (zh) 2017-01-09 2019-09-27 阿德利克斯股份有限公司 Nhe介导的反向转运的抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
CZ300647B6 (cs) * 1998-08-21 2009-07-08 Novartis Ag Pevný farmaceutický prípravek pro perorální podávání obsahující tegaserod nebo jeho farmaceuticky prijatelnou sul
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
CA2379948C (en) * 1999-08-03 2008-03-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions

Also Published As

Publication number Publication date
TW200410684A (en) 2004-07-01
CA2470668A1 (en) 2003-07-03
NZ533585A (en) 2006-04-28
US20050106236A1 (en) 2005-05-19
ES2258171T3 (es) 2006-08-16
EP1321142A1 (en) 2003-06-25
HUP0402492A2 (hu) 2005-07-28
ECSP105163A (es) 2010-07-30
SI1458377T1 (sl) 2006-08-31
CN100464749C (zh) 2009-03-04
PE20030872A1 (es) 2003-11-24
PL369509A1 (en) 2005-04-18
AU2002361198B2 (en) 2006-06-08
US20090104263A1 (en) 2009-04-23
CA2470668C (en) 2011-07-05
KR100980144B1 (ko) 2010-09-03
AU2002361198A1 (en) 2003-07-09
EG24194A (en) 2008-10-14
NO20042779L (no) 2004-09-17
RU2322978C2 (ru) 2008-04-27
ATE320807T1 (de) 2006-04-15
PT1458377E (pt) 2006-07-31
TWI260221B (en) 2006-08-21
MY139546A (en) 2009-10-30
EP1458377A1 (en) 2004-09-22
DE60210139D1 (de) 2006-05-11
MXPA04006157A (es) 2004-10-27
AR037937A1 (es) 2004-12-22
ZA200404467B (en) 2006-05-31
DE60210139T2 (de) 2006-08-17
JP4718776B2 (ja) 2011-07-06
HUP0402492A3 (en) 2008-04-28
CO5640102A2 (es) 2006-05-31
HU226589B1 (en) 2009-04-28
CN1606438A (zh) 2005-04-13
DK1458377T3 (da) 2006-06-12
KR20040066922A (ko) 2004-07-27
IL162451A (en) 2009-02-11
WO2003053432A1 (en) 2003-07-03
IL162451A0 (en) 2005-11-20
JP2005516946A (ja) 2005-06-09
RU2004122631A (ru) 2005-08-10
EP1458377B1 (en) 2006-03-22
CY1105559T1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
BR0215148A (pt) Composições farmacêuticas de agonista parcial 5ht4
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
BR0204001A (pt) Forma de dosagem oral sólida de simeticona
BR9802487A (pt) Composicões de simeticona/fosfato de cálcio anídrico.
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
BRPI0409250B8 (pt) Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
BRPI0412489A (pt) composição de confeito mastigável liberando para as superfìcies dentárias uma dose unitária de uma enzima
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR9810658A (pt) Composições farmacêuticas contendo hemissulfato de eletriptano e cafeìna.
BR0114727A (pt) Método para suprimir o mau odor oral e prover proteção de hálito duradoura na cavidade oral
BR0316906A (pt) administração do capsaicinoides
CY1118179T1 (el) Φαρμακευτικη συνθεση
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BR0308955A (pt) Produto oral e composição
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
MXPA04001250A (es) Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6).
BR0214497A (pt) Composição farmacêutica que compreende um agonista do receptor 5ht1
BR0208813A (pt) Composições contendo imidazotriazinona para a aplicação nasal

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/404; A61K 9/20; A61P 1/00

Ipc: A61K 31/404 (2011.01), A61K 9/20 (2011.01), A61P 1

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.